Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05827042

Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion

Led by The First Affiliated Hospital of University of Science and Technology of China · Updated on 2024-10-01

338

Participants Needed

1

Research Sites

151 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To assess the effect of endovascular thrombectomy alone compared to intravenous thrombolysis plus endovascular thrombectomy in acute basilar artery occlusion patients within 4.5 hours from onset on efficacy and safety outcomes.

CONDITIONS

Official Title

Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with symptoms of posterior circulation ischemic stroke due to basilar artery occlusion or vertebral artery occlusions preventing blood flow into the basilar artery
  • Stroke onset to randomization within 4.5 hours
  • Age 18 years or older
  • Confirmed basilar or vertebral artery occlusion by CTA, MRA, or DSA
  • Eligible for both endovascular thrombectomy and intravenous thrombolysis
  • Baseline NIH Stroke Scale score of 10 or higher
  • Signed informed consent from patient or legal representative
Not Eligible

You will not qualify if you...

  • Evidence of intracerebral hemorrhage on CT or MR (less than 10 microbleeds allowed)
  • Pre-stroke modified Rankin scale score of 2 or higher
  • Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) below 6 on CT or below 5 on MRI-DWI
  • Pregnant or lactating women
  • Allergy to contrast agent or nitinol alloy
  • Life expectancy less than 1 year
  • Vascular tortuosity, anatomical variation, or artery dissection making endovascular treatment difficult
  • Participation in other clinical trials
  • Uncontrolled high blood pressure (systolic >185 mmHg or diastolic >110 mmHg)
  • Blood clotting disorders or anticoagulant issues
  • Blood glucose below 50 mg/dl or above 400 mg/dl, or low platelet count
  • Severe kidney problems or need for dialysis
  • Unable to complete 90-day follow-up
  • Acute ischemic cerebral infarction within 3 months
  • History or suspicion of cerebral vasculitis or infectious endocarditis
  • Nervous system disease or mental disorder before stroke affecting assessment
  • Large cerebellar infarction with space occupying effect
  • Extensive bilateral thalamic or brainstem infarction
  • Both anterior and posterior circulation large vessel occlusion
  • Intracranial tumors except small meningiomas
  • Received intravenous thrombolytic treatment before randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China, 230001

Actively Recruiting

Loading map...

Research Team

W

Wei Hu, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here